Trial Profile

A phase II study of durvalumab (MEDI 4736) maintenance in frail limited disease small cell lung cancer patients after thoracic chemoradiotherapy (CRT)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary)
Indications Small cell lung cancer
Focus Therapeutic Use
Acronyms DURVALUNG

Most Recent Events

15 Jun 2025 Given protocol has been amended as above-1) Number of treatment arms has been changed from 2 to 1.2) Parallel and randomization study designs has been removed. 3) Planned number of patients has been changed from 550 to 100.
15 Jun 2025 Planned number of patients changed from 550 to 100.
15 Jun 2025 Planned End Date changed from 30 Mar 2029 to 24 Feb 2030.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com